JP2024517143A5 - - Google Patents

Info

Publication number
JP2024517143A5
JP2024517143A5 JP2023565530A JP2023565530A JP2024517143A5 JP 2024517143 A5 JP2024517143 A5 JP 2024517143A5 JP 2023565530 A JP2023565530 A JP 2023565530A JP 2023565530 A JP2023565530 A JP 2023565530A JP 2024517143 A5 JP2024517143 A5 JP 2024517143A5
Authority
JP
Japan
Prior art keywords
dystrophin
region
pharmaceutical composition
raav
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026341 external-priority patent/WO2022232141A1/en
Publication of JP2024517143A publication Critical patent/JP2024517143A/ja
Publication of JP2024517143A5 publication Critical patent/JP2024517143A5/ja
Pending legal-status Critical Current

Links

JP2023565530A 2021-04-26 2022-04-26 ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与 Pending JP2024517143A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163180064P 2021-04-26 2021-04-26
US63/180,064 2021-04-26
US202163245909P 2021-09-19 2021-09-19
US63/245,909 2021-09-19
US202263314436P 2022-02-27 2022-02-27
US63/314,436 2022-02-27
US202263319363P 2022-03-13 2022-03-13
US63/319,363 2022-03-13
PCT/US2022/026341 WO2022232141A1 (en) 2021-04-26 2022-04-26 Microdystrophin gene therapy administration for treatment of dystrophinopathies

Publications (2)

Publication Number Publication Date
JP2024517143A JP2024517143A (ja) 2024-04-19
JP2024517143A5 true JP2024517143A5 (cg-RX-API-DMAC7.html) 2025-05-12

Family

ID=81654620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565530A Pending JP2024517143A (ja) 2021-04-26 2022-04-26 ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与

Country Status (9)

Country Link
US (2) US20240216543A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517143A (cg-RX-API-DMAC7.html)
KR (1) KR20240004564A (cg-RX-API-DMAC7.html)
BR (1) BR112023021999A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216744A1 (cg-RX-API-DMAC7.html)
IL (1) IL307902A (cg-RX-API-DMAC7.html)
TW (1) TW202309293A (cg-RX-API-DMAC7.html)
WO (1) WO2022232141A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
EP4493226A1 (en) * 2022-03-13 2025-01-22 RegenxBio Inc. Modified muscle-specific promoters
WO2024138158A2 (en) 2022-12-23 2024-06-27 Ultragenyx Pharmaceutical Inc. Method of producing soluble microdystrophin protein and uses of the same
WO2025225719A1 (en) * 2024-04-26 2025-10-30 Chugai Seiyaku Kabushiki Kaisha Treatment and prevention of muscular dystrophy and its related diseases or disorders with satralizumab
CN118490245B (zh) * 2024-05-11 2025-12-12 北京邮电大学 一种基于心电波形监督的压力识别方法
WO2026006341A1 (en) 2024-06-24 2026-01-02 Regenxbio Inc. Microdystrophin gene therapy administration for treatment of dystrophinopathies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7183969B2 (en) 2004-12-22 2007-02-27 Raytheon Company System and technique for calibrating radar arrays
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
WO2008088895A2 (en) * 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
AU2009215987B2 (en) 2008-02-19 2015-01-22 Uniqure Ip B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
DK2425000T3 (da) 2009-04-30 2019-05-13 Univ Pennsylvania Sammensætninger rettet mod ledende luftvejsceller omfattende konstrukter af adeno-associeret virus
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2016115543A2 (en) * 2015-01-16 2016-07-21 University Of Washington Novel micro-dystrophins and related methods of use
GB201507842D0 (en) * 2015-05-07 2015-06-17 New Royal Holloway & Bedford Production of large-sized microdystrophins in an AAV-based vector configuration
JP6665466B2 (ja) 2015-09-26 2020-03-13 日亜化学工業株式会社 半導体発光素子及びその製造方法
WO2017070491A1 (en) 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations
EP3498293A1 (en) * 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CA3086942A1 (en) 2018-02-07 2019-08-15 Genethon Hybrid regulatory elements
AU2020392243A1 (en) * 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof

Similar Documents

Publication Publication Date Title
JP2022511776A5 (cg-RX-API-DMAC7.html)
JP2024532619A5 (cg-RX-API-DMAC7.html)
TW201919714A (zh) 用於aav之遞送之組合物及方法
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP7413629B2 (ja) Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療
JP2021534154A5 (cg-RX-API-DMAC7.html)
WO2023009554A1 (en) Methods to reduce adverse effects of gene or biologics therapy
JP2018522063A (ja) グルカゴン類似ペプチド−1受容体亢進剤を含む筋減少症治療用薬学組成物
WO2023108159A1 (en) Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
Chiriboga Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies: CA Chiriboga
JP2025506681A5 (cg-RX-API-DMAC7.html)
JP2022060514A (ja) ガバペンチノイドからの干渉が減少し、hgf異型体を発現するdnaコンストラクトを用いる神経病症の治療
JP2017503022A (ja) インビボで細胞に活性型テロメラーゼを提供する組成物および方法
JP2025508841A5 (cg-RX-API-DMAC7.html)
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
KR20160145820A (ko) 알츠하이머병(ad)의 치료 및 예방
US12630840B2 (en) One-step gene therapy for Duchenne muscular dystrophy via gene replacement and anti-inflammation
KR20160145821A (ko) 알츠하이머병(ad)의 치료 및 예방
AU2022401717A1 (en) Combinatorial therapeutic approach for friedreich's ataxia
KR20160145822A (ko) 알츠하이머병(ad)의 치료 및 예방
CN110475573A (zh) 用于减少肌脂蛋白表达以及预防和治疗肌营养不良症和心肌病的组合物及其使用方法
JP2023512688A (ja) 脊髄損傷後の機能回復を促進するためのマイクロrna-7組成物およびその使用方法
US20240209360A1 (en) Products and methods for inducing exon 2 skipping of the dmd gene in treating muscular dystrophy
KR20240170759A (ko) 단백질 고효율 발현용 mRNA 구조체 플랫폼
WO2025096910A1 (en) Cpg-free codon-optimized human microdystrophin for duchenne muscular dystrophy gene therapy